Fosamax and Osteonecrosis of the Jaw: Understanding the Biological Plausibility

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of Informed Decision-Making in Health Communication

The legacy of general health and science communication has long emphasized the importance of informed decision-making and awareness of potential risks associated with medical treatments. Within this tradition, the dissemination of information about prescription medications has been a cornerstone, helping patients and healthcare providers navigate therapeutic benefits alongside possible adverse effects. This heritage naturally extends to the domain of bone health, where bisphosphonates like Fosamax have been widely prescribed for conditions such as osteoporosis. As public understanding of medication side effects evolved, attention turned to rare but serious complications, including osteonecrosis of the jaw (ONJ). The biological plausibility of this association rests on the drug's mechanism of action, which involves inhibition of bone resorption, potentially impairing the jaw's ability to remodel and repair itself after minor trauma or dental procedures. This foundational knowledge, rooted in general health education, now serves as a bridge to more specialized concerns.

From General Health to Occupational Exposure: A Transition

In occupational settings, such as those involving healthcare workers or dental professionals who may handle or administer these medications, the focus shifts from patient-centered risk awareness to workplace exposure considerations. Understanding the transition from general health contexts to occupational exposure requires recognizing how the same biological principles apply when individuals encounter Fosamax not as patients but through their professional duties, thereby broadening the scope of risk assessment and safety protocols. This section bridges the general health legacy with the specific medical evidence that follows.

Biological Plausibility of Fosamax-Associated Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The biological plausibility of this association is supported by mechanistic pathways, clinical presentation, and documented risk factors. Osteonecrosis of the jaw can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition involves bone death due to compromised blood supply and impaired bone remodeling. Bisphosphonates like Fosamax inhibit osteoclast activity, reducing bone resorption. While this effect is beneficial for increasing bone mass and reducing fracture risk in osteoporosis, it can also suppress normal bone turnover. In the jaw, which undergoes constant remodeling due to mechanical stress from chewing and dental procedures, this suppression may lead to accumulation of microdamage and inability to repair bone, predisposing to necrosis. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents provides insight into these mechanisms. Studies using estrogen-deficient rat models have examined the effects of bisphosphonate (alendronate) treatment on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). Such research helps understand jawbone-specific responses to bisphosphonate therapy and the development of bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The findings suggest that bisphosphonate treatment alters the mechanical and structural properties of jawbone, potentially increasing vulnerability to necrosis.

Risk Factors and Clinical Evidence

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Regarding adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section describes the condition, associated risk factors, and recommendations for management, including discontinuation of treatment for patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation Considerations

Causation considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and ONJ onset, excluding other potential causes such as cancer, radiation therapy, or other medications. The presence of known risk factors, such as dental procedures or poor oral hygiene, may contribute to the development of ONJ in patients taking Fosamax. The biological plausibility of the association is supported by the drug's mechanism of action and evidence from preclinical studies. However, the low incidence of ONJ in clinical trials and the similarity of symptom rates between Fosamax and placebo groups suggest that individual susceptibility and co-factors play a significant role. In summary, the evidence supports a plausible biological link between Fosamax and osteonecrosis of the jaw, mediated by bisphosphonate-induced suppression of bone turnover and altered jawbone properties. The prescribing information provides warnings and risk mitigation strategies, but the condition remains a rare but serious adverse event that requires clinical awareness and appropriate management.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological plausibility of Fosamax causing osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast activity, reducing bone resorption. While beneficial for osteoporosis, this suppression can impair normal bone turnover in the jaw, which undergoes constant remodeling. This may lead to accumulation of microdamage and inability to repair bone, predisposing to necrosis. Studies have shown that bisphosphonate treatment alters the mechanical and structural properties of jawbone, potentially increasing vulnerability to ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the known risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ symptoms appear?

The time to onset of symptoms can range from one day to several months after starting the drug. Most patients experience relief after stopping Fosamax, but some may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.